Results 201 to 210 of about 99,677 (264)

IL6 blockade: an effective approach in steroid-refractory immune checkpoint inhibitor-related neuropathies requiring ICI rechallenge-case report. [PDF]

ESMO Open
Baek C, Kramkimel N, Mélé N, Lenglet T, Psimaras D, Birzu C.   +5 more
europepmc   +1 more source

The Impact of Study Size on COVID‐19 Treatment Outcomes: A Meta‐Epidemiological Study Comparing Large and Small Randomized Controlled Trials

Reviews in Medical Virology, Volume 36, Issue 2, March 2026.
ABSTRACT Small randomized controlled trials (RCTs) in COVID‐19 meta‐analyses have been associated with more favourable treatment effects and reduced result stability. This study assessed how trial size impacts effect estimates, statistical stability, and risk of bias.
Dong Hyun Kim, Soojin Lim, Michael Eisenhut, Andreas Kronbichler, Eunyoung Kim, Min Seo Kim, Stefania I. Papatheodorou, Justin Stebbing, Yonghong Peng, Sarah Soyeon Oh, Jae Il Shin, Lee Smith   +11 more
wiley   +1 more source

Benefit and risk associated with interleukin-6 receptor inhibitor administration during severe COVID-19: a retrospective multicentric study. [PDF]

Sci Rep
Lefèvre C, Funck-Brentano T, Cachanado M, Plocque A, Youinou M, Fels A, Pène F, Savale L, Montani D, Voisin O, Bintein F, Wildenberg L, Philippe A, Legriel S, Roche N, Burgel PR, Tran M, Noël N, Baillard C, Duranteau J, Chatellier G, Philippart F.   +21 more
europepmc   +1 more source

Role of Interleukin-6 in Atherothrombosis and Myocardial Infarction. [PDF]

Curr Atheroscler Rep
Huse C, Gregersen I, Holme FA, Ueland T, Skjelland M, Aamodt AH, Dahl TB, Aukrust P, Halvorsen B.   +8 more
europepmc   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, Volume 183, Issue 6, Page 1271-1287, March 2026.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Long-term follow-up of linear scleroderma en coup de sabre in children with central nervous system involvement. [PDF]

Front Immunol
Chang X, Ren L, Wu Y, Zhang Y, Wei C, Zhang Q, Zhang M, Zhao C, Bao X.   +8 more
europepmc   +1 more source

Efficacy and Safety of Rituximab Versus Inebilizumab in Patients With Neuromyelitis Optica Spectrum Disorder: A Dual‐Center, Real‐World Cohort Study

European Journal of Neurology, Volume 33, Issue 3, March 2026.
In our real‐world study of 276 patients, rituximab and inebilizumab demonstrated comparable efficacy in the medium term but differed in their safety profiles, with a significantly higher incidence of infusion‐related reactions observed in the rituximab group.
Ying Cui, Zihao Yu, Hengri Cong, Hao Zhang, Yutong Shi, Ai Guo, Yujing Li, Dongmei Jia, Chao Zhang, Kaibin Shi, Fu‐Dong Shi, Wei Jiang   +11 more
wiley   +1 more source

IL-1R/IL-6R blockade for null NLRP12 variant-carrying Takayasu arteritis. [PDF]

Rheumatology (Oxford)
Argyropoulou OD, Marinakis NM, Charalampopoulos G, Tilemis FN, Liasis N, Manoussakis MN.   +5 more
europepmc   +1 more source

Dermal Fibroblasts, Not Keratinocytes, Dominate IL‐17A/TNF‐Driven Inflammation

Experimental Dermatology, Volume 35, Issue 3, March 2026.
ABSTRACT Chronic inflammatory skin diseases such as psoriasis and hidradenitis suppurativa are driven by cytokines, including IL‐17A and TNF. Although biologics targeting these cytokines have transformed therapy, the transcriptional contributions of individual skin‐resident cell types remain unclear, and dermal fibroblasts have been largely overlooked ...
Lejla Svraka, Hakim Ben Abdallah, Trine Bertelsen, Christian Vestergaard, Claus Johansen   +4 more
wiley   +1 more source

Effectiveness and safety of tocilizumab in refractory noninfectious uveitis: a systematic review and meta-analysis. [PDF]

Front Pharmacol
Kang H, Wu X, Xu H, Huang Y, Zhang M.
europepmc   +1 more source